Approval · Notice of Compliance 27339 · 2022
SIMLANDI: Notice of Compliance 27339
Issued January 5, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27339
- Date
- January 5, 2022
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- HUMIRA
Products in this notice
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.4ML
- ADALIMUMAB 80 MG per 0.8ML
- ADALIMUMAB 40 MG per SYR